Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

Drug Development of Intranasal Insulin for Smoking Cessation

3:30 pm - 4:30 pm, March 14, 2018

Department of Biopharmaceutical Sciences presents:  Research Seminar

"Drug Development of Intranasal Insulin for Smoking Cessation"

Ajna Hamidovic, PharmD, MS
Assistant Professor
Department of Pharmacy Practice
University of Illinois at Chicago

March 14, 2018 (Wednesday)
3:30 PM – 4:30 PM
Room B36 / E226 Rockford
833 S. Wood Street
Chicago, IL

Abstract: A significant barrier to drug development for smoking cessation is the inability to deliver therapeutic compounds through the blood brain barrier. The direct nose-to-brain delivery, which is accomplished by a targeted deposition of compounds to the highly innervated olfactory region, my overcome this difficulty. We administered intranasal insulin to abstinent smokers in two clinical trials and showed that the neuropeptide rapidly decreases nicotine cravings. I will first describe neurobiological basis for CNS insulin therapy, followed by regulatory challenges in obtaining IND approval. I will also review the nose-to-brain pathway as well as present results of our clinical trial. The novel nicotine dependence pharmacotherapy with intranasal insulin has an overarching goal of reducing morbidity and mortality caused by smoking.

Event Details

Location: UIC College of Pharmacy
Room: B36 COP/E226 Rockford
Address:
833 S. Wood Street
CHICAGO, IL

Sponsor: Biopharmaceutical Sciences, Department of

Contact Name: Biopharmaceutical Sciences
Contact Email: tkuzmis@uic.edu
Contact Phone: 312-996-0888

This event displayed:

Date Posted: Mon, Mar 5
Date Updated: Mon, Mar 5

Share this event

Top